$3.25
1.72% yesterday
Nasdaq, Dec 03, 10:00 pm CET
ISIN
US98420X1037
Symbol
XFOR

X4 Pharmaceuticals, Inc. Stock price

$3.25
-0.84 20.54% 1M
-0.71 17.93% 6M
-18.76 85.23% YTD
-7.84 70.70% 1Y
-35.45 91.60% 3Y
-198.65 98.39% 5Y
-2,522.15 99.87% 10Y
-2,522.15 99.87% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+0.06 1.72%
ISIN
US98420X1037
Symbol
XFOR
Industry

Key metrics

Basic
Market capitalization
$318.3m
Enterprise Value
$272.1m
Net debt
positive
Cash
$122.2m
Shares outstanding
25.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
9.4 | 8.8
EV/Sales
8.0 | 7.6
EV/FCF
negative
P/B
5.2
Financial Health
Equity Ratio
15.1%
Return on Equity
-169.1%
ROCE
-70.6%
ROIC
-277.8%
Debt/Equity
1.2
Financials (TTM | estimate)
Revenue
$34.0m | $36.0m
EBITDA
$-97.6m | -
EBIT
$-98.9m | $-80.8m
Net Income
$-95.1m | $-94.7m
Free Cash Flow
$-106.1m
Growth (TTM | estimate)
Revenue
2,933.9% | 1,305.9%
EBITDA
25.1% | -
EBIT
24.4% | 42.8%
Net Income
-467.4% | -152.9%
Free Cash Flow
20.2%
Margin (TTM | estimate)
Gross
83.2%
EBITDA
-287.2% | -
EBIT
-291.1%
Net
-279.9% | -263.2%
Free Cash Flow
-312.3%
More
EPS
$-3.8
FCF per Share
$-4.2
Short interest
2.2%
Employees
143
Rev per Employee
$20.0k
Show more

Is X4 Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

X4 Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a X4 Pharmaceuticals, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a X4 Pharmaceuticals, Inc. forecast:

Buy
91%
Hold
9%

Financial data from X4 Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
34 34
2,934% 2,934%
100%
- Direct Costs 5.70 5.70
1,040% 1,040%
17%
28 28
4,389% 4,389%
83%
- Selling and Administrative Expenses 51 51
9% 9%
151%
- Research and Development Expense 76 76
1% 1%
223%
-98 -98
25% 25%
-287%
- Depreciation and Amortization 1.33 1.33
129% 129%
4%
EBIT (Operating Income) EBIT -99 -99
24% 24%
-291%
Net Profit -95 -95
467% 467%
-280%

In millions USD.

Don't miss a Thing! We will send you all news about X4 Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

X4 Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
3 days ago
X4 Pharmaceuticals is a single-asset biotech built around Mavorixafor. This is approved for WHIM in the US, and the next step is a label expansion for CN. XFOR's 4WARD Phase 3 trial in CN will be key. This could unlock a sizeable TAM across 15,000 patients with moderate-to-severe symptoms. Mavorixafor's initial Phase 2 data showed that once-daily oral doses helped with ANC and may reduce G-CSF ...
Neutral
GlobeNewsWire
29 days ago
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Second Annual Healthcare Innovation Conference on November 10-12, 2025 in Boston. The X4 team will hold a fireside chat on November 10th at 8:30 a.m.
Neutral
GlobeNewsWire
29 days ago
Company's strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trial Previously announced workforce reductions resulted in $13M annualized cost savings Successful completion of two financial transactions totaling $240.3M; cash runway now extends to the end of 2028 BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a compa...
More X4 Pharmaceuticals, Inc. News

Company Profile

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.

Head office United States
CEO Paula Ragan
Employees 143
Founded 2010
Website www.x4pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today